KLRK1 and neoplasm: NKG2D, expressed on natural killer cells (NK cells) and T cells, activates lymphocytes by recognising major histocompatibility complex I (MHC I)‐like ligands on tumour cells, thereby enhancing immune capacity and eliminating tumour cells.233, 234, 235, 236